Muutke küpsiste eelistusi

E-raamat: Antiviral Chemotherapy 4: New Directions for Clinical Application and Research

Edited by , Edited by , Edited by
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 221,68 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Antiviral Chemotherapy 4: New Directions for Clinical Application and ResearchSuurem pilt
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

The three years since our last conference in San Francisco have again seen a dramatic expansion of the number of antivirals either licensed or in the late stages of clinical trials. d4T is now licensed for HIV infection, famciclovir and the oral pro-drug of acyclovir, valacyclovir, are now licensed for VZV infections in some countries. Moreover. oral ganciclovir, cidofovir, and sorivudine are not far behind. Clinical trials with the second-site reverse transcriptase inhibitors and the protease inhibitors for HlV infection are proceeding rapidly and on a broad scale, and the preliminary results would suggest that several of these classes of drugs will be licensed as well. Despite this optimism, however, there is increasing evidence that antiviral-resistant strains of pathogenic viruses will be a significant problem, perhaps especially with therapy of HIV infection, and there remains a desperate need for improved drugs (with either improved efficacy or decreased toxicity, or both) for CMV and HIV infections. This book is the edited proceedings of the Fourth Triennial Conference on Antiviral Chemotherapy, held in San Francisco, in November 1994. The conference was sponsored by the University of California, San Francisco, and co-sponsored by the International Society for Antiviral Research (ISAR), the Macfarlane Burnet Centre for Medical Research in Melbourne, Australia, and the Australian National Centre for HIV Virology Research. The conference had been organized to present an overview of the field of antiviral chemotherapy.
Management of Genital Herpes.- Subclinical Shedding of HSV: Its
Potential for Reduction by Antiviral Therapy.- Famciclovir: Efficacy in
Zoster and Issues in the Assessment of Pain.- Valacyclovir Hcl (ValtrexTM):
An Acyclovir Prodrug with Improved Pharmacokinetics and Better Efficacy for
Treatment of Zoster.- Sorivudine: A Potent Inhibitor of Varicella Zoster
Virus Replication.- Summary of Panel Discussion about Antiviral Therapy for
Zoster.- Antiviral Drug Resistance in Herpes Simplex Virus.- Treatment of
Acyclovir-Resistant Herpes Simplex and Varicella Zoster Virus Infections.-
Therapeutic Immunization for Recurrent Herpes Simplex Virus Infections.-
Current Management of Cytomegalovirus Retinitis in AIDS Update on Ganciclovir
and Foscarnet for CMV Infections.- Oral Ganciclovir for Cytomegalovirus
Infections.- A Preclinical and Clinical Overview of the Nucleotide-Based
Antiviral Agent Cidofovir (HPMPC).- Prophylaxis and Treatment of CMV
Infections in Transplantation.- Cytomegalovirus: Genetics of Drug
Resistance.- Immunotherapy of CMV Infections.- Hantavirus Infections in the
United States: Diagnosis and Treatment.- Management of Respiratory Syncytial
Virus Infections.- Update on Therapy of Influenza and Rhinovirus Infections.-
Therapy for Chronic Hepatitis B Infection.- Treatment of Chronic Hepatitis C
Virus Infection: A Clinical and Virological Perspective.- Zidovudine: Anno
1995.- The Clinical Use of Didanosine.- ddC (Zalcitabine).- Stavudine (d4T,
Zerit®).- Delavirdine Mesylate, a Potent Non-Nucleoside HIV-1 Reverse
Transcriptase Inhibitor.- Clinical Experience with Non-Nucleoside Reverse
Transcriptase Inhibitors: L-697,661 and Nevirapine.- Current Clinical
Experience with Nevirapine for HIV Infection.- Saquinavir: An HIV Proteinase
Inhibitor.- Perspectives in HIVProtease Inhibitors.- In Vivo Selection of
HIV-1 Variants with Reduced Susceptibility to the Protease Inhibitor
L-735,524 and Related Compounds.- Controversies in Initiating Anti-Retroviral
Therapy and in the Use of Combination Therapies.- Use of Antiretroviral
Therapy in Children and Pregnant Women.- Efficacy of Combination
Antiretroviral Therapy.- New Initiatives in Combination Antiretroviral
Chemotherapy.- Antiretroviral Drug Resistance: Mechanisms, Pathogenesis,
Clinical Significance.- Promising Anti-HIV Compounds in Preclinical or Early
Clinical Development.- Enhancing HIV-1 Specific Immunity as a Therapeutic
Strategy in AIDS.- Cytokine Therapy of HIV Infection.- Gene Therapy for HIV-1
Infection.
Lisainfo e-raamatute kohta Lisainfo e-raamatute kohta
Püsilink: https://www.kriso.ee/db/97814757920962e.html
Märksõnad: